Literature DB >> 28634843

Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence.

Biao Zheng1,2, Kenoki Ohuchida3,4, Zilong Yan2, Takashi Okumura2, Takao Ohtsuka2, Masafumi Nakamura5.   

Abstract

BACKGROUND: The pattern of recurrence affects the clinical outcome in tumor patients. However, the clinical significance of lung metastasis as the primary recurrence site after resection in patients with pancreatic cancer remains unclear. This study aimed to clarify the clinical significance of the primary recurrence site in patients with pancreatic cancer, in terms of prognosis and clinicopathological features.
METHODS: This retrospective cohort study included 220 patients with postoperative recurrence after pancreatectomy for pancreatic cancer and classified by primary site of recurrence. We focused on patients with lung metastasis as the primary recurrence and investigated its correlation with prognosis and clinicopathological factors.
RESULTS: Twenty-four (11%) patients had lung metastasis as the primary recurrence. This recurrence pattern had the best prognosis among all recurrence patterns, including liver metastasis and local recurrence. Patients with lung metastasis as the primary recurrence had favorable overall survival and survival from the date of recurrence compared with patients with other primary recurrence sites in both univariate (P = 0.0008 and P = 0.0005) and multivariate analyses (P = 0.0051 and P = 0.0068). In terms of clinicopathological features of resected pancreatic tumors, lung metastasis as the primary recurrence was associated with lower tumor stage and histologic grade, and less vascular invasion and residual tumor volume than liver metastasis.
CONCLUSIONS: Pancreatic cancer patients with lung metastasis as the primary recurrence after pancreatectomy have a better prognosis than those with other recurrence patterns.

Entities:  

Mesh:

Year:  2017        PMID: 28634843     DOI: 10.1007/s00268-017-4068-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  28 in total

1.  Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Authors:  Nicholas J Vogelzang; Steven I Benowitz; Sylvia Adams; Carol Aghajanian; Susan Marina Chang; Zoann Eckert Dreyer; Pasi A Janne; Andrew H Ko; Greg A Masters; Olatoyosi Odenike; Jyoti D Patel; Bruce J Roth; Wolfram E Samlowski; Andrew D Seidman; William D Tap; Jennifer S Temel; Jamie H Von Roenn; Mark G Kris
Journal:  J Clin Oncol       Date:  2011-12-05       Impact factor: 44.544

2.  PULMONARY MANIFESTATIONS OF CARCINOMA OF THE PANCREAS.

Authors:  J R LISA; S TRINIDAD; M B ROSENBLATT
Journal:  Cancer       Date:  1964-03       Impact factor: 6.860

3.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

4.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

5.  Pancreatic Cancer Registry in Japan: 20 years of experience.

Authors:  Seiki Matsuno; Shinichi Egawa; Shoji Fukuyama; Fuyuhiko Motoi; Makoto Sunamura; Shuji Isaji; Toshihide Imaizumi; Shuichi Okada; Hiroyuki Kato; Kouichi Suda; Akimasa Nakao; Takehisa Hiraoka; Ryo Hosotani; Kazunori Takeda
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

6.  Lung recurrence after curative surgery for colorectal cancer.

Authors:  E Pihl; E S Hughes; F T McDermott; W R Johnson; H Katrivessis
Journal:  Dis Colon Rectum       Date:  1987-06       Impact factor: 4.585

7.  Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer.

Authors:  Stephan Kruger; Michael Haas; Philipp Johannes Burger; Steffen Ormanns; Dominik Paul Modest; Christoph Benedikt Westphalen; Marlies Michl; Axel Kleespies; Martin Kurt Angele; Werner Hartwig; Christiane Josephine Bruns; Maximilian Niyazi; Falk Roeder; Thomas Kirchner; Jens Werner; Volker Heinemann; Stefan Boeck
Journal:  Pancreatology       Date:  2016-03-30       Impact factor: 3.996

8.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.

Authors:  M Wagner; C Redaelli; M Lietz; C A Seiler; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2004-05       Impact factor: 6.939

Review 9.  Metastatic pulmonary adenocarcinoma 13 years after curative resection for pancreatic cancer: report of a case and review of Japanese literature.

Authors:  Yuhei Kitasato; Masamichi Nakayama; Gen Akasu; Munehiro Yoshitomi; Kazuhiro Mikagi; Yuichiro Maruyama; Ryuichi Kawahara; Hiroto Ishikawa; Toru Hisaka; Masafumi Yasunaga; Hiroyuki Horiuchi; Naoyuki Saito; Shinzo Takamori; Yoshinobu Okabe; Masayoshi Kage; Hisafumi Kinoshita; Hiroyuki Tanaka
Journal:  JOP       Date:  2012-05-10

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  13 in total

1.  Long-term survival after repeated resection of metachronous lung metastases from pStage IA pancreatic adenocarcinoma.

Authors:  Mamoru Miyasaka; Takehiro Noji; Kazuto Ohtaka; Ryohei Chiba; Shoki Sato; Yasuhito Shoji; Ryunosuke Hase; Tatsunosuke Ichimura; Satoshi Hirano; Naoto Senmaru
Journal:  Clin J Gastroenterol       Date:  2017-10-16

2.  Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer.

Authors:  Toshihide Sasaki; Satoshi Nishiwada; Kenji Nakagawa; Minako Nagai; Taichi Terai; Daisuke Hokuto; Satoshi Yasuda; Yasuko Matsuo; Shunsuke Doi; Masayuki Sho
Journal:  Int J Clin Oncol       Date:  2022-02-10       Impact factor: 3.402

3.  Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Retrospective Study.

Authors:  Koki Hayashi; Yoshihiro Ono; Manabu Takamatsu; Atsushi Oba; Hiromichi Ito; Takafumi Sato; Yosuke Inoue; Akio Saiura; Yu Takahashi
Journal:  Ann Surg Oncol       Date:  2022-03-01       Impact factor: 5.344

4.  Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy.

Authors:  Giuseppe A Colloca; Antonella Venturino; Domenico Guarneri
Journal:  Med Oncol       Date:  2018-10-29       Impact factor: 3.064

5.  Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Ding Ding; Ammar A Javed; Richard A Burkhart; Jun Yu; Inne H Borel Rinkes; I Quintus Molenaar; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg Oncol       Date:  2018-06-14       Impact factor: 5.344

6.  Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study.

Authors:  Taro Mashiko; Akira Nakano; Yoshihito Masuoka; Seiichiro Yamamoto; Soji Ozawa; Toshio Nakagohri
Journal:  BMC Surg       Date:  2021-05-05       Impact factor: 2.102

7.  Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection.

Authors:  Chaobin He; Zhiyuan Cai; Yu Zhang; Xiaojun Lin
Journal:  J Oncol       Date:  2021-10-21       Impact factor: 4.375

8.  Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report.

Authors:  Ryota Matsuki; Masanori Sugiyama; Hidefumi Takei; Haruhiko Kondo; Masachika Fujiwara; Junji Shibahara; Junji Furuse
Journal:  Surg Case Rep       Date:  2018-03-27

9.  A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection.

Authors:  Chaobin He; Xin Huang; Yu Zhang; Zhiyuan Cai; Xiaojun Lin; Shengping Li
Journal:  Front Oncol       Date:  2019-11-12       Impact factor: 6.244

10.  LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer.

Authors:  Biao Zheng; Jianhua Qu; Kenoki Ohuchida; Haimin Feng; Stephen Jun Fei Chong; Zilong Yan; Yicui Piao; Peng Liu; Nan Sheng; Daiki Eguchi; Takao Ohtsuka; Kazuhiro Mizumoto; Zhong Liu; Shazib Pervaiz; Peng Gong; Masafumi Nakamura
Journal:  Theranostics       Date:  2020-08-13       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.